Estimation of risk factors influencing the results of treatment in patients with new-onset pulmonary tuberculosis

A demand arose for estimating the risk factors influencing the results of treatment for their objective assessment in patients with new-onset pulmonary tuberculosis.

Objective: to estimate risk factors influencing the results of treatment in patients with new-onset pulmonary tuberculosis to provide a rationale for new approaches to their registration and treatment assessment.

Subjects and methods. Information about 227 pulmonary tuberculosis patients registered to be treated in the Ryazan Regional Tuberculosis Dispensary in 2011 was obtained from the reporting forms of the Ministry of Health of Russia. For their analysis, an inquiry schedule consisting of 32 characteristics was worked out. The methods of a multifactorial analysis were applied.

Results. The multifactorial analysis showed that there was a deep relationship between two factors: bacterial excretion and pulmonary cavitation. It was determined that the number of cohorts of pulmonary tuberculosis patients to be registered should be increased from 4 to 6. An effective treatment outcome, or clinical resolution, is indicative of the presence of two signs (cessation of bacterial excretion and closure of pulmonary cavities) and it is a uniform criterion for assessing the results of treatment in all patents with pulmonary tuberculosis regardless of the cohort they had been registered in. Changing a treatment regimen requires that the patient should be re-registered in another respective cohort. 

1. Левашев Ю. Н., Репин Ю. М. Руководство по легочному и внелегочному туберкулезу. - СПб.: ЭЛБИ-СПб., 2006. - 515 с.

2. Мишин В. Ю., Чуканов В. И., Васильева И. А. Эффективность лечения туберкулеза легких, вызванного микобактериями с множественной лекарственной устойчивостью // Пробл. туб. - 2002. - № 12. - С. 18-23

3. Мотус И. Я., Голубев Д. Н., Баженов А. В. и др. Хирургия туберкулеза легких // Туб. - 2012. - № 6. - С. 14-20.

4. Туберкулез: выявление, лечение и мониторинг по К. Томену. Вопросы и ответы / пер. с англ. - М.: Весь мир, 2004. - 387 с.

5. Chaulk C. P., Kazandjian V. A. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel // JAMA. - 1998. - Vol. 279. - P. 943-948.

6. Espinal M. A., Kim S. J., Suarez P. G. et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries // JAMA. - 2000. - Vol. 283. - P. 2537-2545.

7. Faustini A., Hall A. J., Perucci C. A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review // Thorax. - 2006. - Vol. 61. - P. 158-163.

8. Implementing the WHO Stop TB strategy: a handbook for national tuberculosis control program. World Health Organization. - Geneva, 2008. - 125 pp.

9. World Health Organization. The global plan to stop TB 2006-2015. Geneva, Switzerland: Stop TB Partnership, 2006. http://www.who.int/tb/features_archive/global_plan_to_stop_tb